U.S. Pancreatic Cancer Treatment Market Size & Outlook
U.S. pancreatic cancer treatment market, 2018-2030 (US$M)
Related Markets
U.S. pancreatic cancer treatment market highlights
- The U.S. pancreatic cancer treatment market generated a revenue of USD 1,018.9 million in 2024 and is expected to reach USD 2,010.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 12% from 2025 to 2030.
- In terms of segment, exocrine was the largest revenue generating type in 2024.
- Endocrine is the most lucrative type segment registering the fastest growth during the forecast period.
Pancreatic cancer treatment market data book summary
| Market revenue in 2024 | USD 1,018.9 million |
| Market revenue in 2030 | USD 2,010.7 million |
| Growth rate | 12% (CAGR from 2025 to 2030) |
| Largest segment | Exocrine |
| Fastest growing segment | Endocrine |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Exocrine, Endocrine |
| Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.9% of the global pancreatic cancer treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. pancreatic cancer treatment market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 65.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pancreatic Cancer Treatment Market Scope
Pancreatic Cancer Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. pancreatic cancer treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.39% in 2024. Horizon Databook has segmented the U.S. pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. pancreatic cancer treatment market is highly competitive, led by key players such as AstraZeneca, Novartis AG, and Pfizer Inc., leveraging established therapies and pioneering innovations.
According to the WHO, there were 60,127 new cases in 2022 and over 50,000 deaths each year. Pancreatic cancer ranks as the third leading cause of cancer-related mortality in the U.S., underscoring the demand for effective treatments.
AstraZeneca has made strides with olaparib, a PARP inhibitor for BRCA-mutated cases, while Novartis AG focuses on immunotherapies targeting the tumor microenvironment, and Pfizer Inc.
Reasons to subscribe to U.S. pancreatic cancer treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. pancreatic cancer treatment market databook
-
Our clientele includes a mix of pancreatic cancer treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. pancreatic cancer treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
US Type - Pancreatic Cancer Treatment Market size, 2024 - 2030 (US$M)
U.S. Pancreatic Cancer Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
